Steven Pieper, Chief Financial Officer of Xeris Biopharma Holdings Inc., sold 5,000 shares of common stock on September 1 for $42,500, or $8.50 per share, according to a regulatory filing.
The disposal was executed pursuant to a Rule 10b5-1 trading plan adopted on August 18, 2025, and did not reflect any change in the company’s operational outlook. Pieper retained 1,356,053 shares of Xeris Biopharma common stock following the transaction.
Xeris Biopharma’s shares have gained 38% over the past six months, though the stock remains on InvestingPro’s watchlist for potential overvaluation relative to its fair-value estimate. The company’s second-quarter 2026 results showed revenue of $92.1 million, a 29% increase year-over-year and above Wall Street expectations. Earnings, however, fell short, with a loss of $0.18 per share compared with a projected profit of $0.01 per share.
Revenue growth was driven by strong demand for RECORLEV and a recovery in sales of Gvoke. The earnings miss was attributed in part to a one-time non-cash GAAP charge related to convertible note remeasurement.
